Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
Published Online: 30 DEC 2013
Assessed as up-to-date: 3 MAR 2011
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Arbyn M, Bryant A, Martin-Hirsch PPL, Xu L, Simoens C, Markowitz L. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD009069. DOI: 10.1002/14651858.CD009069.pub2.
- Publication Status: Edited (no change to conclusions), comment added to review
- Published Online: 30 DEC 2013
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types). We will assess clinical effectiveness by evaluating outcomes in all women, irrespective of the HPV DNA or serology status at enrolment. Evaluation by fine age and time since sexual debut categories is also planned.